How much did Bio-Path Holdings raise?

Bio-Path Holdings raised $318,000 in a Seed round on March 25, 2024.

Who are the decision-makers at Bio-Path Holdings?

Fundz holds 2 contacts at Bio-Path Holdings. Names and contact details are shown to Fundz members.

Bio Path Holdings reported raising $318,000 in an initial SEC Form D filing, from an offering of $318,000

TAKEN PRIVATEApr 05, 2024

Amount Raised

$318,000

$318,000 sold, per SEC Form D (first sale Mar 25, 2024)

Round Type

Seed

BellaireBiotechnology

Quick answer

Bio-Path Holdings raised $318,000 in a Seed round, dated March 25, 2024. Bio-Path Holdings is based in Bellaire, Texas, United States.

How much did Bio-Path Holdings raise?: Bio-Path Holdings raised $318,000 in a Seed round on March 25, 2024.
What does Bio-Path Holdings do?: Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other challenging cancers.
Where is Bio-Path Holdings based and how big is it?: Bio-Path Holdings is based in Bellaire, Texas, United States.
Who are the decision-makers at Bio-Path Holdings?: Fundz holds 2 contacts at Bio-Path Holdings. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Bio-Path Holdings that raised within 45 days of this round, from Fundz verified event records.

Elegen raised $33M on May 9, 2024.
R3 Vascular raised $87M (Series B) on May 9, 2024.
Alzamend Neuro raised $25M (Series A) on May 9, 2024.
Eledon raised $50M on May 9, 2024.
Aardvark Therapeutics raised $85M (Series C) on May 9, 2024.
Frequency Exchange raised $210K (Pre-Seed) on May 9, 2024.

Who to call at Bio-Path Holdings, and when

A new round usually means Bio-Path Holdings is about to hire and buy. The teams that reach out first get the meeting.

An alert the day Bio-Path Holdings raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Bio-Path Holdings, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Bio-Path Holdings. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Bio-Path Holdings

Location

4710 BELLAIRE BOULEVARD

Bellaire, Texas, United States

About

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other challenging cancers. The company’s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in previously untreated AML patients, who are not eligible for or who have decided to forego intensive chemotherapy because of their fragile health, and in refractory/relapsed AML patients. Additionally, BP1001-A is being assessed in a Phase 1 study in refractory/relapsed patients with solid tumors. The Company’s second product BP1002 (Liposomal Bcl-2 Antisense) is being evaluated in Phase 1 trials in patients with refractory/relapsed lymphoma and AML.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Bio-Path Holdings raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans

Related People

2 contacts

Predictive Intelligence

Strategic

ML-powered predictions for Bio-Path Holdings's next move

See what Strategic adds

Bio-Path Holdings raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

Show me how a sales rep uses this Or see plans and pricing →

5 screens from a live account. No signup.